The pathophysiology and treatment of proteasome inhibitor induced polyneuropathy
Project/Area Number |
26860659
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Neurology
|
Research Institution | Chiba University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 化学療法誘発性末梢神経障害 / プロテアソーム阻害薬 / 下肢感覚神経 / 軸索イオンチャネル機能評価 / 化学療法誘発性ポリニューロパチー / プロテオソーム阻害薬 / 化学療法性末梢神経障害 / プロテアソーム阻害剤 / 神経軸索機能検査 / 薬剤性ニューロパチー |
Outline of Final Research Achievements |
Chemotherapy induced polyneuropathy (CIPN) is one of thr frequent side effect of proteasome inhibitor and become most popular regulatory factor for decreasing the dose.The pathophysiology of CIPN are still unknown and the evaluation is difficult because main symptom is sensory disturbance at lower extremities. The present study showed that using a near nerve needle would make easier to evaluate nerve excitability in sensory nerve at lower extermities. This technique would contribute to evaluate CIPN which is mainly impared in sensory nerve in lower extremities.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
[Journal Article] Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.2016
Author(s)
Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, et al; Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group.
-
Journal Title
Lancet Neurol
Volume: 15
Issue: 11
Pages: 1129-37
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-